941 related articles for article (PubMed ID: 23663001)
21. Perampanel: expanding therapeutic options for patients with medically refractory secondary generalized convulsive seizures.
Ko D; Ramsay RE
Acta Neurol Scand Suppl; 2013; (197):36-43. PubMed ID: 23480155
[TBL] [Abstract][Full Text] [Related]
22. Psychiatric and behavioral adverse events in randomized clinical studies of the noncompetitive AMPA receptor antagonist perampanel.
Ettinger AB; LoPresti A; Yang H; Williams B; Zhou S; Fain R; Laurenza A
Epilepsia; 2015 Aug; 56(8):1252-63. PubMed ID: 26140524
[TBL] [Abstract][Full Text] [Related]
23. A randomized phase III trial of adjunctive zonisamide in pediatric patients with partial epilepsy.
Guerrini R; Rosati A; Segieth J; Pellacani S; Bradshaw K; Giorgi L
Epilepsia; 2013 Aug; 54(8):1473-80. PubMed ID: 23837461
[TBL] [Abstract][Full Text] [Related]
24. Adverse effects and safety profile of perampanel: a review of pooled data.
Rugg-Gunn F
Epilepsia; 2014 Jan; 55 Suppl 1():13-5. PubMed ID: 24400692
[TBL] [Abstract][Full Text] [Related]
25. Analysis of pooled phase III trials of adjunctive perampanel for epilepsy: Impact of mechanism of action and pharmacokinetics on clinical outcomes.
Kwan P; Brodie MJ; Laurenza A; FitzGibbon H; Gidal BE
Epilepsy Res; 2015 Nov; 117():117-24. PubMed ID: 26448264
[TBL] [Abstract][Full Text] [Related]
26. Efficacy and safety of eslicarbazepine acetate as adjunctive treatment in adults with refractory partial-onset seizures: a randomized, double-blind, placebo-controlled, parallel-group phase III study.
Elger C; Halász P; Maia J; Almeida L; Soares-da-Silva P;
Epilepsia; 2009 Mar; 50(3):454-63. PubMed ID: 19243424
[TBL] [Abstract][Full Text] [Related]
27. Dose-dependent safety and efficacy of zonisamide: a randomized, double-blind, placebo-controlled study in patients with refractory partial seizures.
Brodie MJ; Duncan R; Vespignani H; Solyom A; Bitenskyy V; Lucas C
Epilepsia; 2005 Jan; 46(1):31-41. PubMed ID: 15660766
[TBL] [Abstract][Full Text] [Related]
28. Perampanel in the treatment of partial seizures: Time to onset and duration of most common adverse events from pooled Phase III and extension studies.
Ko D; Yang H; Williams B; Xing D; Laurenza A
Epilepsy Behav; 2015 Jul; 48():45-52. PubMed ID: 26057204
[TBL] [Abstract][Full Text] [Related]
29. Final safety, tolerability, and seizure outcomes in patients with focal epilepsy treated with adjunctive perampanel for up to 4 years in an open-label extension of phase III randomized trials: Study 307.
Krauss GL; Perucca E; Kwan P; Ben-Menachem E; Wang XF; Shih JJ; Patten A; Yang H; Williams B; Laurenza A
Epilepsia; 2018 Apr; 59(4):866-876. PubMed ID: 29574701
[TBL] [Abstract][Full Text] [Related]
30. Randomized, double-blind, placebo-controlled trial of ezogabine (retigabine) in partial epilepsy.
French JA; Abou-Khalil BW; Leroy RF; Yacubian EM; Shin P; Hall S; Mansbach H; Nohria V;
Neurology; 2011 May; 76(18):1555-63. PubMed ID: 21451152
[TBL] [Abstract][Full Text] [Related]
31. Efficacy of perampanel: a review of pooled data.
Steinhoff BJ
Epilepsia; 2014 Jan; 55 Suppl 1():9-12. PubMed ID: 24400691
[TBL] [Abstract][Full Text] [Related]
32. Long-term safety and efficacy in patients with uncontrolled partial-onset seizures treated with adjunctive lacosamide: results from a Phase III open-label extension trial.
Husain A; Chung S; Faught E; Isojarvi J; McShea C; Doty P
Epilepsia; 2012 Mar; 53(3):521-8. PubMed ID: 22372628
[TBL] [Abstract][Full Text] [Related]
33. Perampanel, a novel, non-competitive, selective AMPA receptor antagonist as adjunctive therapy for treatment-resistant partial-onset seizures.
Rektor I
Expert Opin Pharmacother; 2013 Feb; 14(2):225-35. PubMed ID: 23259931
[TBL] [Abstract][Full Text] [Related]
34. Long-term effects of adjunctive perampanel on cognition in adolescents with partial seizures.
Piña-Garza JE; Lagae L; Villanueva V; Renfroe JB; Laurenza A; Williams B; Kumar D; Meador KJ
Epilepsy Behav; 2018 Jun; 83():50-58. PubMed ID: 29653338
[TBL] [Abstract][Full Text] [Related]
35. Perampanel: as adjunctive therapy in patients with partial-onset seizures.
Plosker GL
CNS Drugs; 2012 Dec; 26(12):1085-96. PubMed ID: 23179642
[TBL] [Abstract][Full Text] [Related]
36. Safety and tolerability of lacosamide as adjunctive therapy for adults with partial-onset seizures: Analysis of data pooled from three randomized, double-blind, placebo-controlled clinical trials.
Biton V; Gil-Nagel A; Isojarvi J; Doty P; Hebert D; Fountain NB
Epilepsy Behav; 2015 Nov; 52(Pt A):119-27. PubMed ID: 26414341
[TBL] [Abstract][Full Text] [Related]
37. Safety and efficacy of two pregabalin regimens for add-on treatment of partial epilepsy.
Beydoun A; Uthman BM; Kugler AR; Greiner MJ; Knapp LE; Garofalo EA;
Neurology; 2005 Feb; 64(3):475-80. PubMed ID: 15699378
[TBL] [Abstract][Full Text] [Related]
38. A pooled analysis of lacosamide clinical trial data grouped by mechanism of action of concomitant antiepileptic drugs.
Sake JK; Hebert D; Isojärvi J; Doty P; De Backer M; Davies K; Eggert-Formella A; Zackheim J
CNS Drugs; 2010 Dec; 24(12):1055-68. PubMed ID: 21090839
[TBL] [Abstract][Full Text] [Related]
39. Long-term safety of perampanel and seizure outcomes in refractory partial-onset seizures and secondarily generalized seizures: results from phase III extension study 307.
Krauss GL; Perucca E; Ben-Menachem E; Kwan P; Shih JJ; Clément JF; Wang X; Bagul M; Gee M; Zhu J; Squillacote D
Epilepsia; 2014 Jul; 55(7):1058-68. PubMed ID: 24867391
[TBL] [Abstract][Full Text] [Related]
40. Efficacy and safety of adjunctive ezogabine (retigabine) in refractory partial epilepsy.
Brodie MJ; Lerche H; Gil-Nagel A; Elger C; Hall S; Shin P; Nohria V; Mansbach H;
Neurology; 2010 Nov; 75(20):1817-24. PubMed ID: 20944074
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
